Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
2.420
-0.040 (-1.63%)
At close: Mar 27, 2026, 4:00 PM EDT
2.425
+0.005 (0.21%)
After-hours: Mar 27, 2026, 4:04 PM EDT
Evotec SE Employees
Evotec SE had 4,788 employees as of September 30, 2025. The number of employees decreased by 219 or -4.37% compared to the same quarter last year.
Employees
4,788
Change
-219
Growth
-4.37%
Revenue / Employee
$185,338
Profits / Employee
-$38,958
Market Cap
879.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 4,788 | -219 | -4.37% |
| Jun 30, 2025 | 4,759 | -263 | -5.24% |
| Mar 31, 2025 | 4,766 | -289 | -5.72% |
| Dec 31, 2024 | 4,740 | -321 | -6.34% |
| Sep 30, 2024 | 5,007 | -79 | -1.55% |
| Jun 30, 2024 | 5,022 | -45 | -0.89% |
| Mar 31, 2024 | 5,055 | 103 | 2.08% |
| Dec 31, 2023 | 5,061 | 109 | 2.20% |
| Sep 30, 2023 | 5,086 | 371 | 7.87% |
| Jun 30, 2023 | 5,067 | 546 | 12.08% |
| Dec 31, 2022 | 4,952 | 754 | 17.96% |
| Sep 30, 2022 | 4,715 | 634 | 15.54% |
| Jun 30, 2022 | 4,521 | 607 | 15.51% |
| Mar 31, 2022 | 4,354 | 619 | 16.57% |
| Dec 31, 2021 | 4,198 | 626 | 17.53% |
| Sep 30, 2021 | 4,081 | 637 | 18.50% |
| Jun 30, 2021 | 3,914 | 636 | 19.40% |
| Mar 31, 2021 | 3,735 | 705 | 23.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Perrigo Company | 8,100 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Alvotech | 1,012 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Collegium Pharmaceutical | 423 |
| Harrow | 373 |
EVO News
- 2 days ago - EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 2 days ago - EQS-AFR: Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 6 days ago - Evotec SE: Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - Finanz Nachrichten
- 6 days ago - Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - Accesswire
- 10 days ago - Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation - Accesswire
- 18 days ago - Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 19 days ago - Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript - Seeking Alpha
- 19 days ago - Evotec SE Analyst Call Transcript - GuruFocus